Neuropsychopharmacology of delta-9-tetrahydrocannabinol;Neuropsychopharmacologie du delta-9-tétrahydrocannabinol (THC)

Annales Pharmaceutiques Francaises

Volumn 66, Issue 4, 2008, Pages 219-231

  Costentin, J ^a,b,c  

^a UNIVERSITÉ DE ROUEN   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

^c Institut fédératif de recherche multidisciplinaire sur les peptides 23   (France)

Author keywords

Cannabis; CB1 receptors; Endocannabinoids; Psychotoxicity; Toxicomania

Indexed keywords

ALCOHOL; CANNABINOID 1 RECEPTOR; CANNABIS; DIAMORPHINE; DRONABINOL; ENDOCANNABINOID; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL;

ALCOHOL ABUSE; ANXIETY; ARTICLE; ATAXIA; BRAIN REGION; CANNABIS ADDICTION; CANNABIS SMOKING; COGNITIVE DEFECT; COORDINATION DISORDER; DEPRESSION; DRUG WITHDRAWAL; EXCRETION; EXTRACELLULAR SPACE; HUMAN; LUNG; MEMBRANE; MOTOR DYSFUNCTION; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA; TOBACCO DEPENDENCE; TRANQUILIZING ACTIVITY; CHEMICALLY INDUCED DISORDER; COGNITION; DRUG EFFECT; NERVOUS SYSTEM; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; PSYCHOSIS; REVIEW;

ANXIETY; COGNITION; DEPRESSION; ENDOCANNABINOIDS; HUMANS; MARIJUANA ABUSE; MARIJUANA SMOKING; NERVOUS SYSTEM; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTROPIC DRUGS; RECEPTOR, CANNABINOID, CB1; SCHIZOPHRENIC PSYCHOLOGY; TETRAHYDROCANNABINOL;

EID: 58149170213     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2008.07.003     Document Type: Article

References (106)

1. Costentin J. Le cannabis - données neurobiologiques récentes éclairant les perturbations de la conduite des véhicules. Ann Pharm Fr 64 (2006) 148-159
2. Chabrol H., and Roura C. Le « bong » un mode fréquent et méconnu de consommation du cannabis. Courrier Addict 6 (2004) 28-31
3. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
4. Ohlson N., Lindgren J.E., Wahlen A., Agurell S., Hollister L.E., and Gillespie H.K. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28 (1980) 409-416
5. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87 (1990) 1986-1992
6. Smith-Kieland A., Skuterud B., and Morland J. Urinary excretion of 11-NOR-9-carboxy-Δ9 tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 23 (1990) 323-332
7. Gifford A.N., Bruneus M., Gatley S.J., and Volkow N.D. Cannabinoid receptor - mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes. Br J Pharmacol 13 (2000) 645-650
8. Rapport OFDT (Office français des drogues et toxicomanies) publié le 10 juillet 2007.
9. Tsou K., Patrick S.L., and Walker J.M. Physical withdrawal in rats tolerant to Δ-9 tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280 (1995) R13-R15
10. Aceto M.D., Scates S.M., Lowe J.A., and Martin B.R. Cannabinoid precipitated withdrawal by the selective antagonist, SR 141716A. Eur J Pharmacol 282 (1995) R1-R2
11. Hutcheson D.M., Tzavara E.T., Smadja C., Valjent E., Roques B.P., Hanoune J., et al. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Δ-9-tetrahydrocannabinol. Brit J Pharmacol 125 (1998) 1567-1577
12. Cook S.A., Lowe J.A., and Martin B.R. CB1 receptor antagonist precipitates withdrawal in mice exposed to Δ-9 tetrahydrocannabinol. J Pharmacol Exp Ther 285 (1998) 1150-1156
13. Wu X., and French E.D. Effects of chronic Δ-9 tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology 39 (2000) 391-398
14. Tanda G., Loddo P., and Di Chiara G. Dependence of mesolimbic dopamine transmission on Δ-9 tetrahydrocannabinol. Europ J Pharmacol 376 (1999) 23-26
15. Gonzalez S., Cebeira M., and Fernandez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboraty animals. Pharmacol Biochem Behav 81 (2005) 300-318
16. da Silva G.E., Morato G.S., and Takahaschi R.N. Rapid tolerance to Δ9 tetrahydrocannabinol and cross tolerance between ethanol and Δ9 tetrahydrocannabinol in mice. Europ J Pharmacol 431 (2001) 201-207
17. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
18. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
19. Oka S., Arai S., Waku K., Tokumara A., and Sugiura T. Depolarization-induced rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand in rat brain synaptosomes. J Biochem 141 (2007) 687-697
20. Sugiura T., Kobayashi Y., Oka S., and Waku K. Biosynthesis and degradation of anandamide and 2 arachidonylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 173-192
21. Alger B.E. Endocannabinoids: getting the message across. Proc Natl Acad Sci U S A 101 (2004) 8512-8513
22. Schlicker E., and Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22 (2001) 565-572
23. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signalling. Physiol Rev 83 (2003) 1017-1066
24. Wenger T., Nordrich G., and Furst S. Neuromorphological backgrounds of cannabis addiction. Brain Res Bull 61 (2003) 125-128
25. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
26. Hillard C.J., and Jarraltian A. The movement of N-arachidonoyl ethanolamine (anandamide) accross cellular membranes. Chem Phys Lipids 108 (2000) 123-134
27. Fowler C.J. The cannabinoid system and its pharmacological manipulation - a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol 20 (2006) 549-562
28. Bisogno T., Ligresti A., and Di Marzo V. The endocannabinoid signalling system: Biochemical aspects. Pharmacol Biochem Behav 81 (2005) 224-238
29. Sañudo-Peña M.C., Romero J., Seale G.E., Fernandez-Ruiz J.J., and Walker J.M. Activational role of cannabinoids on movement. Eur J Pharmacol 391 (2000) 269-274
30. Hagues D., Costentin J., and Duterte-Boucher D. Modulation of morphine and alcohol motor stimulant effects by cannabinoid receptors ligands. Behav Brain Res 178 (2007) 274-282
31. Dar M.S. Cerebellar CB1 receptor mediation of Δ-9 THC-induced motor incoordination and its potentiation by ethanol and modulation by cerebellar adenosinergic A1 receptor in the mouse. Brain Res 864 (2000) 186-194
32. Laumon B., Gadegbeku B., Martin J.L., and Biecheler M.B. SAM group cannabis intoxication and fatal road crashes in France: population base case - control study. Brit Med J 331 (2005) 1371-1379
33. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol 63 (2001) 569-611
34. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20 (1999) 287-294
35. Gong J.-P., Onaivi E.S., Ishiguro H., Liu Q.-R., Tagliaferro P.A., Brusco A., et al. Cannabinoid receptors: immunohistochemical localization in rat brain. Brain Res 1071 (2006) 10-23
36. Cichewicz D.L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74 (2004) 1317-1324
37. Beltramo M., Bernardini N., Bertorelli R., Campanella M., Nicolussi E., Fredduzzi S., et al. CB2 receptor-mediated antihyperalgesia possible direct involvement of neural mechanisms. Eur J Neurosci 23 (2006) 1530-1538
38. Fride E., Ginzburg Y., Breuer A., Bisogno T., Di Marzo V., and Mechoulam R. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 419 (2001) 207-214
39. Scheen A.J., Finer N., Hollander P., Jensen M.D., and Van Gaal L.F. For the RIO-Diabetes study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 3678 (2006) 1660-1672
40. Jamshidi N., and Taylor D.A. Anandamide administration in the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134 (2001) 1151-1154
41. Darmani N.A., and Johnson J.C. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488 (2004) 201-212
42. Costentin J. Données neurobiologiques sur le cannabis en 2006. In: Nordmann R, editor. Désamorcer le cannabis dès l'école. Rapports de l'Académie nationale de médecine. Paris: Éditions Lavoisier; 2006, p. 31-64.
43. Campbell V.A. Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome C release and caspase 3 activation. Neuropharmacology 40 (2001) 702-709
44. Mishima K., Egashira N., Matsumoto Y., Iwasaki K., and Fujiwara M. Involvement of reduced acetylcholine release in Δ-9 tetrahydrocannabinol-induced impairment of spatial memory in the 8-arm radial maze. Life Sci 2 (2002) 397-407
45. Lichtman A.H., Varvel S.A., and Martin B.R. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 269-285
46. Fride E. Endocannabinoids in the central nervous system: from neuronal networks to behaviour. Curr Drug Targets 4 (2005) 633-642
47. Robbe D., Montgomery S.M., Thome A., Rueda-Orozco P.E., McNaughton B.L., and Buzsaki G. Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nature Neurosci 6 (2006) 1526-1533
48. Viveros M.P., Marco E.M., and File S.E. Endocannabinoid system and stress and anxiety reponses. Pharmacol Biochem Behav 81 (2005) 331-342
49. Martin M., Ledent C., Parmentier M., Maldonado R., and Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159 (2002) 379-387
50. Arévalo C., de Miguel R., and Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 70 (2001) 123-131
51. Navarro M., Hernandez E., Munoz R.M., del Arco J., Villanueva M.A., Carrere M.R., et al. Acute administration of the CB1 receptor antagonist SR141716A induces anxiety like response in the rat. Neuroreport 8 (1997) 491-496
52. Griebel G., Stemmelin J., and Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in modele of emotional reactivity in rodents. Biol Psychiatry 57 (2005) 261-267
53. Degenhardt L., Hall W., and Linskey M. The relationship between cannabis use, depression and anxiety among australian adults: Findings from the national survey of mental health and well being. Soc Psychiatr Epidemiol 36 (2001) 219-227
54. Choquet M. À 17 ans un adolescent sur 6 consomme régulièrement du cannabis. In: Huerre P, Marty F, editors. Cannabis et adolescence - les liaisons dangereuses. Éditions Albin Michel; 2004, p. 17-26.
55. Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997;56:803-7.
56. Favrat B., Menetrey A., Augsburger M., Rothuisen L.E., Appenzeler M., Buclin T., et al. Two cases of "cannabis acute psychosis" following the administration of oral cannabis. BMC Psychiatry 5 (2005) 17
57. Moreau de Tours J. Du cannabis et de l'aliénation mentale. Édition princeps Masson;1845 (rééditée en 1980, Paris-Genève: Éditions Slatkine).
58. Tennant F.S., and Groesbeck C.J. Psychiatric effects of haschich. Arch Gen Psychiatry 27 (1972) 133-136
59. Andreasson S., Allebeck P., Engström A., and Rydberg U. Cannabis and schizophrenia. Lancet 2 (1987) 1483-1486
60. Zammit S., Allebeck P., Andreasson S., Lundberg I., and Lewis G. Self reported cannabis use as a risk factor of schizophrenia in Swedish conscripts of 1969: historical cohort study. Br Med J 325 (2002) 1199-1205
61. Arseneault M.-L., Cannon M., Poulton R., Murray R., Caspi A., and Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br Med J 325 (2002) 1212-1213
62. Van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., and Verdoux H. Cannabis use and psychosis: a longitudinal population based study. Am J Epidemiol 156 (2002) 319-327
63. Henquet C., Krabrendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., et al. Prospective cohort study of cannabis use, predisposition for psychosis symptoms in young people. Br Med J (2005) 330-341
64. Fergusson D.M., Horwood L.J., and Swain-Campbell N.B. Cannabis dependence and psychotic symptoms in young people. Psychol Med 33 (2003) 15-21
65. Fergusson D.M., and Horwood L.J. Does cannabis use encourage other form of illicit drug use. Addiction 95 (2000) 505-520
66. Schneider M., and Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28 (2003) 1760-1769
67. Schneider M., and Koch M. Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effect of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 5 (2005) 944-957
68. Bilder R.M., Volavka J., Lachman H.M., and Grace A.A. The catechol-O-methyltransferase polymorphism relations to the tonic - phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 11 (2004) 1943-1961
69. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent- onset cannabis use on adult psychosis by a functional polymorphism in the catechol O methyl transferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57 (2005) 1117-1127
70. Kovasnay B., Fleischer J., Tanenberg-Karant M., Jandorf L., Miller A.D., and Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 23 (1997) 195-201
71. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29 (2004) 2108-2114
72. Dean B., Sundram S., Bradbury S., Scarr E., and Copolov D. Studies on [3H]-CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103 (2001) 9-15
73. Hungund B.L., Bassavarajappa B.S., Vadasz C., Kunos G., Rodriguez de Fonseca F., Colombo G., et al. Ethanol, endocannabinoids and the cannabinoidergic signalling system. Alcohol Clin Exp Res 26 (2002) 565-574
74. Colombo G., Serra S., Vacca G., Carai M.A.M., Gessa G.L., et al. Endocannabinoid system and alcohol addiction: Pharmacological studies. Pharmacol Biochem Behav 81 (2005) 369-380
75. Manzanares J., Ortiz S., Oliva J.M., Perez-Rial S., and Palomo T. Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects. Alcohol Alcohol 40 (2005) 25-34
76. Arnone M., Maruani J., Chaperon F., Thiébot M.-H., Poncelet M., Soubrié P., et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132 (1997) 104-106
77. Colombo G., Agabio R., Fà M., Mauro F., Guano L., Lobina C., et al. Reduction in voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR 141716. Alcohol Alcohol 33 (1998) 126-130
78. Lallemand F., Soubrié P., and De Witte P.H. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcohol Clin Exp Res 25 (2001) 1317-1323
79. Wang L., Liu J., Harvey-White J., Zimmer A., and Kunos G. Endocannabinoid signalling via cannabinoid receptors is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A 100 (2003) 1393-1398
80. Serra S., Carai M.A.M., Brunetti G., Gomez R., Melis S., Vacca G., et al. The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol preferring rats. Eur J Pharmacol 430 (2001) 369-371
81. Freedland S.J., Sharpe A.L., Samson H.H., and Porrino L.J. Effects of SR 141716A on ethanol and sucrose self administration. Alcohol Clin Exp Res 25 (2001) 277-282
82. Gallate J.E., Saharov T., Mallet P.E., and McGregor J.S. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Europ J Pharmacol 370 (1999) 233-240
83. Colombo G., Vacca G., Serra S., Carai M.A.M., and Gessa G.L. Suppressing effect of the cannabinoid CB1 receptor antagonist SR 141716 on alcohol's motivational properties in alcohol-preferring rats. Europ J Pharmacol 498 (2004) 119-123
84. Cohen C., Perrault G., Votz C., Steinberg R., and Soubrié P. SR 141716, a central cannabinoid CB1 receptor antagonist blocks the motivational and dopamine releasing properties of nicotine in rats. Behav Pharmacol 13 (2002) 451-463
85. Colombo G., Serra S., Brunetti G., Gomez R., Melis S., Vacca G., et al. Stimulation of voluntary intake by cannabinoid receptor agonists in ethanol preferring sP rats. Psychopharmacology 159 (2002) 181-187
86. Hungund B.L., Szakall I., Adam A., Basavarajapa B.S., and Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 84 (2003) 698-704
87. Poncelet M., Maruani J., Calassi R., Soubrié P., and Overeating. alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neuroci Lett 343 (2003) 216-218
88. Naassila M., Pierrefiche O., Ledent C., and Daoust M. Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology 46 (2004) 243-253
89. Thanos P.K., Dimitrakakis E.S., Rice O., Gifford A., and Volkow N.D. Ethanol self-administration and ethanol place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 164 (2005) 206-213
90. Houchi H., Babovic D., Pierrefiche O., Jaffe J.H., and Freedman D.X. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropharmacology 30 (2005) 339-349
91. Chaperon F., Soubrié P., Puech A.J., and Thiébot M.-H. Involvement of central canabinoid CB1 receptor in the establishment of place conditioning in rats. Psychopharmacology 135 (1998) 324-332
92. Braida D., Pozzi M., Cavallini B., and Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55940: Interaction with the opioid system. Neuroscience 104 (2001) 923-926
93. Singh M.E., Verty A.N., McGregor I.S., and Mallet P.E. A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Res 1026 (2004) 244-253
94. Mas-Nieto M., Pommier B., Tzavara E.T., Canaparo A., Da Nascimento S., and Le Fur G. Reduction of opioid dependence by the CB1 antagonist SR 141716A in mice: Evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 132 (2001) 1809-1816
95. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21 (2001) 5344-5350
96. Fratta W., Martelotta M.C., Cossu G., and Frattore L. Self-administration of the cannabinoid agonist Win-55212-2 and morphine in mice; evidence for a common neurobiological mechanism. Eur Neuropsychopharmacol 8 (1998) S41-S42
97. Braida D., Pozzi M., Parolaro D., and Sala M. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: Interaction with the opioid system. Eur J Pharmacol 413 (2001) 227-234
98. De Vries T.J., Homberg J.R., Binnekade R., Raaso H., and Schoffelmeer A.N. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin associated with cues in rats. Psychopharmacology 168 (2003) 164-169
99. Solinas M., Panlilio L.V., Antoniou K., Pappas L.A., and Goldberg S.R. The cannabinoid CB1 antagonist SR 141716A differentially alters the reinforcing effects of heroin under continuous reinforcement fixed ratio and progressive ratio schedules of drug self administration in rats. J Pharmacol Exp Ther 306 (2003) 93-102
100. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.-L., Beslot F., et al. Unresponsiveness to cannabinoid and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
101. Cossu G., Ledent C., Fattore L., Imperato A., Böhme G.A., Parmentier M., et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Brain Res 118 (2001) 61-65
102. Martin M., Ledent C., Parmentier M., Maldonado R., and Valverde O. Cocaine but not morphine induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Pharmacol 12 (2001) 4038-4046
103. Mascia M.S., Obinu M.C., Ledent C., Parmentier M., Böhme G.A., Imperato A., et al. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabis CB1 receptor knockout mice. Eur J Pharmacol 383 (1999) R1-R2
104. Kaymkcalan S., Ayhan I.H., and Tulunay F.C. Naloxone-induced or post withdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats. Psychopharmacology 55 (1977) 243-249
105. Navarro M., Chowen J., Rocio A.C.M., del Arco I., Villanueva M.A., Martin Y., et al. CB1 cannabinoid receptor. Antagonist-induced opiate withdrawal in morphine dependent rats. Neuroreport 9 (1998) 3397-3402
106. Costentin J. Le cannabis un médicament ? In: Halte au cannabis. Éditions Odile Jacob; 2006, p. 99-114.